Potential Securities Fraud: Levi & Korsinsky Investigates Rezolute, Inc. (RZLT)

On December 11, 2025, before the market opened, Rezolute announced topline results from its Phase 3 sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism.

The company reported that the study did not meet its primary endpoint, as it "was not statistically significant to the placebo group, which experienced a 40% improvement.". Further, the study did not meet its key secondary endpoint which was also "not statistically significant to the placebo."

Management expressed disappointment noting "we are conducting a thorough evaluation to gain a better understanding of the study outcomes."

Following this news, RZLT's stock price fell over 89% to open at $1.21 per share.

If you suffered a loss on your Rezolute, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/280792